Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics
Delveinsight
JANUARY 7, 2021
Terns schedules to bring a third candidate into the clinic this year, TERN-501, a thyroid hormone receptor (THR) beta-agonist. Ribometrix will apply its proprietary discovery platform to recognize and optimize small molecule compounds, which modulate RNA function by aiming three-dimensional (3D) RNA structures.
52 
Let's personalize your content